Eslicarbazepine

Eslicarbazepine is an aromatic anticonvulsant similar to oxcarbazepine that is used in combination with other antiepileptic agents as therapy of partial onset seizures. 

Liver safety of Eslicarbazepine

Eslicarbazepine is associated with a low rate of transient serum enzyme elevations during therapy and has been implicated in rare instances of clinically apparent liver injury.

Mechanism of action of Eslicarbazepine

Eslicarbazepine (es" li kar baz' e peen) is an aromatic anticonvulsant related in structure and activity to oxcarbazepine.  Its mechanism of action is unknown but, like other carboxamides, eslicarbazepine is believed to inhibit voltage-gated sodium channels and thereby slow neurotransmission and interrupt the rapid, repetitive firing that is characteristic of epilepsy. 

FDA approval information for Eslicarbazepine

Eslicarbazepine was approved for use in the United States in 2013 as an anticonvulsant to be used alone or in combination with other agents in the therapy of partial onset seizures. 

Dosage and administration for Eslicarbazepine

Eslicarbazepine is available in tablets of 200, 400, 600 and 800 mg under the brand name Aptiom.  The recommended initial dose in adults is 400 mg once daily, which can be increased to 800 to 1600 mg once daily based upon tolerance and effect.  The recommended initial doses in children are 200 to 400 mg once daily based upon body weight with maintenance dosages ranging from 400 to 1200 mg. 

Side effects of Eslicarbazepine

Side effects may include headache, [[dizziness]], ataxia, blurred vision, nausea, [[fatigue]] and tremor.  Rare, but potentially serious adverse events include hyponatremia, suicidal ideation or behavior and hypersensitivity reactions including DRESS and Stevens Johnson syndrome.

• Dailymed label info on Eslicarbazepine
• FDA Eslicarbazepine

Eslicarbazepine Resources
Latest articles Most recent articles Ongoing trials	Wikipedia